Vedolizumab 108mg solution for subcutaneous injection in pre-filled syringe or pre-filled pen (Entyvio®)is accepted for use within NHSScotland for treatment of ulcerative colitis

Accepted for use for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant of either conventional therapy or a tumour necrosis factor-alpha antagonist.


Scottish Medicines Consortium